It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story even if these companies are loss-making. Unfortunately, these high risk investments often have little probability of ever paying off, and many investors pay a price to learn their lesson. A loss-making company is yet to prove itself with profit, and eventually the inflow of external capital may dry up.
If this kind of company isn't your style, you like companies that generate revenue, and even earn profits, then you may well be interested in ALK-Abelló (CPH:ALK B). Even if this company is fairly valued by the market, investors would agree that generating consistent profits will continue to provide ALK-Abelló with the means to add long-term value to shareholders.
How Quickly Is ALK-Abelló Increasing Earnings Per Share?
If you believe that markets are even vaguely efficient, then over the long term you'd expect a company's share price to follow its earnings per share (EPS) outcomes. Therefore, there are plenty of investors who like to buy shares in companies that are growing EPS. To the delight of shareholders, ALK-Abelló has achieved impressive annual EPS growth of 55%, compound, over the last three years. While that sort of growth rate isn't sustainable for long, it certainly catches the eye of prospective investors.
Careful consideration of revenue growth and earnings before interest and taxation (EBIT) margins can help inform a view on the sustainability of the recent profit growth. The good news is that ALK-Abelló is growing revenues, and EBIT margins improved by 6.0 percentage points to 20%, over the last year. That's great to see, on both counts.
You can take a look at the company's revenue and earnings growth trend, in the chart below. Click on the chart to see the exact numbers.
Check out our latest analysis for ALK-Abelló
You don't drive with your eyes on the rear-view mirror, so you might be more interested in this free report showing analyst forecasts for ALK-Abelló's future profits.
Are ALK-Abelló Insiders Aligned With All Shareholders?
Does ALK-Abelló Deserve A Spot On Your Watchlist?
ALK-Abelló's earnings per share growth have been climbing higher at an appreciable rate. Of course, just because ALK-Abelló is growing does not mean it is undervalued. If you're wondering about the valuation, check out this gauge of its price-to-earnings ratio, as compared to its industry.
While opting for stocks without growing earnings and absent insider buying can yield results, for investors valuing these key metrics, here is a carefully selected list of companies in DK with promising growth potential and insider confidence.
Please note the insider transactions discussed in this article refer to reportable transactions in the relevant jurisdiction.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About CPSE:ALK B
ALK-Abelló
An allergy solutions company, develops treatments for respiratory allergy, anaphylaxis, and food allergy and new disease areas in the European Union, the United Kingdom, Norway, Switzerland, the United States, Canada, Japan, China, and internationally.
Flawless balance sheet with solid track record.
Similar Companies
Market Insights
Weekly Picks

Is this the AI replacing marketing professionals?
Pro Medicus: The Market Is Confusing a Lumpy Quarter With a Broken Business
The Rising Deal Risk That Helped Sink Netflix’s $72 Billion Bid for Warner Bros. Discovery
The Infrastructure AI Cannot Be Built Without
Recently Updated Narratives

Hims & Hers Health aims for three dimensional revenue expansion
Zero One +Tive report on Anime & $CTW
ICOP S.p.A. – Investment Narrative and Multibagger Monitoring Framework
Popular Narratives
Nu holdings will continue to disrupt the South American banking market

NVDA: Expanding AI Demand Will Drive Major Data Center Investments Through 2026
